As a member of the prostamide class of ocular hypotensives, bimatoprost (Lumigan®) lowers intraocular pressure (IOP) by a dual mechanism: by increasing both pressure-dependent (presumed trabecular meshwork) and pressure-independent (presumed […]
Prostate cancer develops in the prostate, which is a gland in the male reproductive system. Prostate cancers generally grow slowly. However, aggressive prostate cancers do occur, which are capable of […]
Acute and chronic airways diseases represent a large proportion of the inpatient and outpatient population continuously under the care of pulmonary physicians and primary healthcare providers. This review article aims […]
In Australia, the lifetime risk of developing non-melanoma skin cancer such as basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) is almost 70% for men and 60% for women. […]
Glioblastoma multiforme (GBM) is the most malignant primary human brain cancer and cannot be cured by any therapy available today. Current therapy includes complex treatments of neurosurgical resection, radiotherapy, and […]
Pharmaceutical industry is growing day by day with the aim to develop new drugs extracted from natural products or synthetic chemically produced drug substances, but one thing always remains constant, […]
A biowaiver monograph of pyrazinamide based on literature data together with some additional experimental data is presented. The risks of basing a bioequivalence (BE) assessment on in vitro rather than […]